Clinical Trial: A Phase 2 Study of SL-325 in Crohn's Disease Patients

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07753850) titled 'A Phase 2 Study of SL-325 in Crohn's Disease Patients' on Aug. 04.

Brief Summary: The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease.

The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Crohn's Disease

Intervention: DRUG: SL-325

SL-325 administered intravenously

DRUG: Placebo

Placebo administered intravenously

Recruitment Status: NOT_YET...